S&C was named a Life Sciences “Practice Group of the Year” by Law360. In an interview with the publication, Matt Hurd, Co-Head of S&C’s Healthcare & Life Sciences Group, highlighted the group’s interdisciplinary approach and how the Firm’s Litigation and M&A Groups collaborate for clients.
Last year, S&C helped eliminate Bayer’s liability for talc claims relating to foot powder products Bayer acquired from Merck. S&C also advised Seagen in its $43 billion acquisition by Pfizer, the largest all-cash pharma takeover in history. Pfizer intends to use Seagen’s antibody-drug conjugate technology, a chemotherapy that attacks cancer cells while minimizing harm to healthy cells, to accelerate the next generation of cancer breakthroughs. “It was a tremendous reward for the scientists and other innovators who have researched and developed therapies for years,” Matt told Law360. “Its scientific promise is really extraordinary.”
In other notable matters, S&C’s Life Sciences Group advised Amgen in its $27.8 billion acquisition of Horizon Therapeutics, the largest healthcare merger announced in 2022; Abiomed in its $18 billion acquisition by Johnson & Johnson, the largest-ever all-cash deal in the medtech sector; and Baxter in its $4.25 billion sale of its BioPharma Solutions business.
S&C was named a “Firm of the Year” for its showing in these awards, tied for the most distinctions with nine practices selected.